Skip to main content

Advertisement

SpringerLink
Log in

Alzheimer disease in 2016

Putting AD treatments and biomarkers to the test

  • Year in Review
  • Published:

From Nature Reviews Neurology

View current issue Sign up to alerts

Investigational treatments to impede the progression of Alzheimer disease (AD) are being evaluated in clinical trials, and biomarkers to detect and track the disease are being developed and deployed. Recent findings underscore the importance of ongoing clinical trials and biomarker developments in the understanding, treatment and prevention of AD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Selkoe, D. J. & Hardy, J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol. Med. 8, 595–608 (2016).

    Article  CAS  Google Scholar 

  2. Cummings, J., Morstorf, T. & Lee, G. Alzheimer's drug-development pipeline: 2016. Alzheimers Dement. (NY) 2, 222–232 (2016).

    Google Scholar 

  3. Reiman, E. M. et al. CAP — advancing the evaluation of preclinical Alzheimer disease treatments. Nat. Rev. Neurol. 12, 56–61 (2016).

    Article  CAS  Google Scholar 

  4. Sevigny, J. et al. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature 537, 50–66 (2016).

    Article  CAS  Google Scholar 

  5. Reiman, E. M. Alzheimer's disease: attack on amyloid-β protein. Nature 537, 36–37 (2016).

    Article  CAS  Google Scholar 

  6. Honig, L. S. et al. EXPEDITION 3: a phase 3 trial of solanezumab in mild dementia due to Alzheimer's disease. CTAD http://www.ctad-alzheimer.com/live-expedition-3-webcast (2016).

  7. Schöll, M. et al. PET imaging of tau deposition in the aging human brain. Neuron 89, 971–982 (2016).

    Article  Google Scholar 

  8. Bittner, T. et al. Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1–42) in human cerebrospinal fluid. Alzheimers Dement. 12, 517–526 (2016).

    Article  Google Scholar 

  9. Bacioglu, M. et al. Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron 91, 56–66 (2016).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

E.M.R. is supported by National Institute on Aging grants RF1 AG041705, UF1 AG046150, R01 AG031581 and P30 AG19610.

Author information

Authors and Affiliations

  1. Eric M. Reiman is at the Banner Alzheimer's Institute, 901 E. Willetta Street, Phoenix, Arizona 85006, USA.,

    Eric M. Reiman

Authors
  1. Eric M. Reiman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric M. Reiman.

Ethics declarations

Competing interests

E.M.R. is a scientific adviser to Alkahest, Alzheon, Biogen, CereSpir, Denali and Pfizer. He and his parent organization have received research grants from Genentech/Roche, Novartis/Amgen, and Avid/Lilly. He is the inventor of a patent, entitled “Accelerated evaluation of treatments to prevent clinical onset of Alzheimer's disease.”

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Reiman, E. Putting AD treatments and biomarkers to the test. Nat Rev Neurol 13, 74–76 (2017). https://doi.org/10.1038/nrneurol.2017.1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2017.1

  • Springer Nature Limited

This article is cited by

Search

Navigation